Intractable Allergic RhinitisNCT06887842
Posterior Nasal Nerve Neurectomy for Treatment of Intractable Allergic Rhinitis
A study testing Posterior Nasal Nerve neurectomy in people with Intractable Allergic Rhinitis, run by Kafrelsheikh University at 1 site in Egypt.
Trial summary
This study aims to compare the outcomes of posterior nasal nerve neurectomy in patients with resistant Allergic rhinitis by using three different methods ( surgical resection vs radiofrequency ablation vs surface coblation ) through assesment of functional outcomes, postoperative complications, and impacts on quality… Read more about this study
- Who is it for?
- Ages 16 to 65 years
- Conditions the study is for
- Intractable Allergic Rhinitis
- What is being tested?
- Posterior Nasal Nerve neurectomy
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 84 participants
- Where
- 1 siteEgypt
- Study dates
- 25 Apr 2025to 1 May 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 16 to 65 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients aged 16 to 65 years, fit for surgery, diagnosed as moderate to severe persistent Allergic Rhinitis, as per the ARIA guidelines having 3 or more of the typical symptoms of Allergic Rhinitis including nasal discharge, repeated attacks of sneezing, nasal itching and nasal obstruction.
Who cannot join
- • Patients with Coexisting nasal pathologies that could influence the outcomes of the surgery like: chronic granulomatous diseases of the nose, nasal tumors, chronic sinsitis with or without nasal polyps, etc.
- Patients who had used topical steroid nasal spray, oral or topical antihistamines, oral leukotriene antagonists, oral or tobical nasal decongestants in the last 2 weeks.
- Immunocompromised patients, Systemic disease affecting prognosis such as diabetes mellitus, hypertension,chronic liver failure or heart failure.
- Unwillingness for endoscopic surgery.
- Patients younger than 18 years of age.
- Patients who are unfit for general anesthesia.
- Previous history of nasal surgery
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Posterior Nasal Nerve Surgical Resection Versus Radiofrequency Ablation Versus Surface Coblation for Treatment of Intractable Allergic Rhinitis
This study aims to compare the outcomes of posterior nasal nerve neurectomy in patients with resistant Allergic rhinitis by using three different methods ( surgical resection vs radiofrequency ablation vs surface coblation ) through assesment of functional outcomes, postoperative complications, and impacts on quality of life.
- Conditions
- Intractable Allergic Rhinitis
- Being tested
- Posterior Nasal Nerve neurectomy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Posterior Nasal Nerve neurectomyDevice
Posterior Nasal Nerve neurectomy which is done by surgical resection.
Posterior Nasal Nerve neurectomyDevice
Posterior Nasal Nerve neurectomy which is done by using radiofrequency ablaion.
Posterior Nasal Nerve neurectomyDevice
Posterior Nasal Nerve neurectomy by coblation of the surface of the course of the nerve
| Study group | Role | What they receive |
|---|---|---|
| Posterior nasal neurectomy by surgical resection | Active comparator | Not described Receives: Device: Posterior Nasal Nerve neurectomy |
| Posterior nasal neurectomy by radio- frequency ablation | Active comparator | Not described Receives: Device: Posterior Nasal Nerve neurectomy |
| Surface coblation on area of the course of the Posterior nasal nerve | Active comparator | Not described Receives: Device: Posterior Nasal Nerve neurectomy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Improvement of the four main symptoms (Sneezing ,itching , rhinorrhea ,nasal obstruction)
These symptoms will be assessed using the SNOT-22 rhinologic subdomain questionnaire which is routinely and prospectively administered to all patients, and individual item scores within the rhinologic subdomain (need to blow nose, sneezing, runny nose, cough, post- nasal discharge, and thick nasal discharge) will be tabulated, each symptom will be scored on a scale from 0 to 5 (0 = no problem, 1 = very mild problem, 2 = mild problem, 3 = moderate problem, 4 = severe problem and 5 = problem as bad as it can be).
Measured: Evaluations will be scheduled for 2 weeks, one month, three months, and six months following surgery.
Secondary outcomes (1)
postoperative complications eg. Bleeding, crustations etc, postoperative endoscopic score will be evaluated.
Bleeding assessment using The Modena bleeding score. Postoperative endoscopic score including : (discharge, crust formation ,scarring ) after the operation will be also recorded and documented using the LundKennedy (LK) system.
Measured: 2 weeks, 1M month after the procedure .
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Mar 2025
- Study start25 Apr 2025
- Primary completion10 Apr 2026
- Study completion1 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Intractable Allergic RhinitisStudies of the same condition, open and under way.
- More trials run by Kafrelsheikh UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kafrelsheikh University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Magdi Noaman Othman Orabi, Kafrelsheikh University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06887842
- Sponsor's protocol ID
- KFSIRB200-543
- Status last verified
- May 2025
- First submitted
- 9 Mar 2025
- Last updated
- 19 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Ahilasamy N, Rajendran Dinesh K. [Endoscopic posterior nasal neurectomy]. J Laryngol Otol. 2019 Sep;133(9):825-829. doi: 10.1017/S002221511900166X. Epub 2019 Aug 23. Spanish.
PubMed 31439065
Study at a glance
From the registry record, last updated by the sponsor on 19 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Posterior Nasal Nerve Surgical Resection Versus Radiofrequency Ablation Versus Surface Coblation for Treatment of Intractable Allergic Rhinitis
- ClinicalTrials.gov ID
- NCT06887842
- Acronym / sponsor ID
- KFSIRB200-543
- Conditions
- Intractable Allergic Rhinitis
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Kafrelsheikh UniversityUniversity, hospital or other
- Study start
- 25 Apr 2025 (actual)
- Primary completion
- 10 Apr 2026 (actual)
- Study completion
- 1 May 2026 (actual)
- First posted
- 20 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to compare the outcomes of posterior nasal nerve neurectomy in patients with resistant Allergic rhinitis by using three different methods ( surgical resection vs radiofrequency ablation vs surface coblation ) through assesment of functional outcomes, postoperative complications, and impacts on quality of life.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Posterior nasal neurectomy by surgical resection | Active comparator | Device: Posterior Nasal Nerve neurectomy |
| Posterior nasal neurectomy by radio- frequency ablation | Active comparator | Device: Posterior Nasal Nerve neurectomy |
| Surface coblation on area of the course of the Posterior nasal nerve | Active comparator | Device: Posterior Nasal Nerve neurectomy |
Who may qualify
- Ages
- 16 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (1 listed)
- Patients aged 16 to 65 years, fit for surgery, diagnosed as moderate to severe persistent Allergic Rhinitis, as per the ARIA guidelines having 3 or more of the typical symptoms of Allergic Rhinitis including nasal discharge, repeated attacks of sneezing, nasal itching and nasal obstruction.
Key exclusion criteria (7 listed)
- • Patients with Coexisting nasal pathologies that could influence the outcomes of the surgery like: chronic granulomatous diseases of the nose, nasal tumors, chronic sinsitis with or without nasal polyps, etc.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Posterior Nasal Nerve neurectomyPosterior Nasal Nerve neurectomy which is done by surgical resection. | Device | Posterior nasal neurectomy by surgical resection |
| Posterior Nasal Nerve neurectomyPosterior Nasal Nerve neurectomy which is done by using radiofrequency ablaion. | Device | Posterior nasal neurectomy by radio- frequency ablation |
| Posterior Nasal Nerve neurectomyPosterior Nasal Nerve neurectomy by coblation of the surface of the course of the nerve | Device | Surface coblation on area of the course of the Posterior nasal nerve |
Primary outcome
Improvement of the four main symptoms (Sneezing ,itching , rhinorrhea ,nasal obstruction)
Time frame: Evaluations will be scheduled for 2 weeks, one month, three months, and six months following surgery.
These symptoms will be assessed using the SNOT-22 rhinologic subdomain questionnaire which is routinely and prospectively administered to all patients, and individual item scores within the rhinologic subdomain (need to blow nose, sneezing, runny nose, cough, post- nasal discharge, and thick nasal discharge) will be tabulated, each symptom will be scored on a scale from 0 to 5 (0 = no problem, 1 = very mild problem, 2 = mild problem, 3 = moderate problem, 4 = severe problem and 5 = problem as bad as it can be).
1 secondary outcome
postoperative complications eg. Bleeding, crustations etc, postoperative endoscopic score will be evaluated.
Time frame: 2 weeks, 1M month after the procedure .
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 19 May 2026.
- Results publication: PubMed 31439065Ahilasamy N, Rajendran Dinesh K. [Endoscopic posterior nasal neurectomy]. J Laryngol Otol. 2019 Sep;133(9):825-829. doi: 10.1017/S002221511900166X. Epub 2019 Aug 23. Spanish.
- Individual participant dataSharing planned: Undecided
Related trials for Intractable Allergic Rhinitis
Recruiting
Efficacy and Safety of Ganciclovir Capsules in the Treatment of Refractory Moderate-to-severe Allergic Rhinitis
Rhinitis, Allergic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Posterior Nasal Nerve neurectomy in people with Intractable Allergic Rhinitis, run by Kafrelsheikh University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 19 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Improvement of the four main symptoms (Sneezing ,itching , rhinorrhea ,nasal obstruction) (time frame: Evaluations will be scheduled for 2 weeks, one month, three months, and six months following surgery.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06887842, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2026.